{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T06:16:08Z","timestamp":1777875368491,"version":"3.51.4"},"reference-count":47,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Venous thromboembolism (VTE) is a serious and common complication in cancer patients, and it is the second leading cause of death after cancer itself. Cancer-associated thrombosis (CAT) is an indicator of a poorer prognosis and can lead to treatment delays and increased healthcare costs. This review aims to provide a comprehensive update on the efficacy and safety of tinzaparin in the treatment and prophylaxis of VTE in cancer patients. Methods: This is a narrative review that examines the pharmacological properties of tinzaparin, as well as the results from clinical studies and meta-analyses. It includes a discussion of tinzaparin\u2019s role in special patient populations and its comparison with other anticoagulants. Results: Tinzaparin is a low-molecular-weight heparin (LMWH) that does not accumulate in patients with renal insufficiency, eliminating the need for dose adjustments. Studies have shown that tinzaparin is a safe and effective treatment for CAT, with a favorable safety profile regarding hemorrhagic complications. In the CATCH study, tinzaparin showed a significant reduction in clinically relevant non-major bleeding compared to warfarin. Tinzaparin has also been shown to be more effective than vitamin K antagonists (VKAs) in promoting the recanalization of venous thrombi. A meta-analysis confirmed that tinzaparin was superior to VKAs in preventing VTE recurrence in the long term. Conclusions: While direct oral anticoagulants (DOACs) offer convenience, LMWHs like tinzaparin remain crucial, especially for patients with specific characteristics such as renal insufficiency, complex drug interactions, or a high risk of gastrointestinal bleeding. Tinzaparin\u2019s favorable safety and efficacy, along with its unique pharmacological properties, make it a valuable option for managing VTE in the complex oncology population.<\/jats:p>","DOI":"10.3390\/jcm14196695","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T10:27:53Z","timestamp":1758623273000},"page":"6695","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Crucial Role of Tinzaparin in Managing Venous Thromboembolism in the Cancer Population"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7060-6938","authenticated-orcid":false,"given":"Alfredo","family":"Mauriello","sequence":"first","affiliation":[{"name":"S.C. Cardiology, Institute National Cancer, IRCCS, Foundation \u201cG. Pascale\u201d, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Correra","sequence":"additional","affiliation":[{"name":"Cardiology Department, Ospedali Riuniti University Hospital, Viale Pinto 1, 71122 Foggia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Chiara","family":"Maratea","sequence":"additional","affiliation":[{"name":"S.C. Cardiology, Institute National Cancer, IRCCS, Foundation \u201cG. Pascale\u201d, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5648-4552","authenticated-orcid":false,"given":"Celeste","family":"Fonderico","sequence":"additional","affiliation":[{"name":"S.C. Cardiology, Institute National Cancer, IRCCS, Foundation \u201cG. Pascale\u201d, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arianna","family":"Amata","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Fondazione Policlinico Universitario A. Gemelli, IRCCS, 00168 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4557-5401","authenticated-orcid":false,"given":"Vincenzo","family":"Quagliariello","sequence":"additional","affiliation":[{"name":"S.C. Cardiology, Institute National Cancer, IRCCS, Foundation \u201cG. Pascale\u201d, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9227-0360","authenticated-orcid":false,"given":"Vincenzo","family":"Russo","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Department of Medical and Translational Sciences, \u201cMonaldi Hospital\u201d, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9698-9145","authenticated-orcid":false,"given":"Antonello","family":"D\u2019Andrea","sequence":"additional","affiliation":[{"name":"Cardiology and Intensive Care Unit, Department of Cardiology, Umberto I Hospital, 84014 Nocera Inferiore, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3704-0092","authenticated-orcid":false,"given":"Nicola","family":"Maurea","sequence":"additional","affiliation":[{"name":"S.C. Cardiology, Institute National Cancer, IRCCS, Foundation \u201cG. Pascale\u201d, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ejvs.2008.11.030","article-title":"A Randomised Open-Label Trial Comparing Long-Term Sub-Cutaneous Low-Molecular-Weight Heparin Compared with Oral-Anticoagulant Therapy in the Treatment of Deep Venous Thrombosis","volume":"37","author":"Romera","year":"2009","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Horsted, F., West, J., and Grainge, M.J. (2012). Risk of Venous Thromboembolism in Patients with Cancer: A Systematic Review and Meta-Analysis. PLoS Med., 9.","DOI":"10.1371\/journal.pmed.1001275"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/S0049-3848(16)30092-5","article-title":"Cancer Associated Thrombosis: Risk Factors and Outcomes","volume":"140","author":"Eichinger","year":"2016","journal-title":"Thromb. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1634\/theoncologist.2015-0361","article-title":"A Validated Risk Score for Venous Thromboembolism Is Predictive of Cancer Progression and Mortality","volume":"21","author":"Kuderer","year":"2016","journal-title":"Oncologist"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer: ASCO Clinical Practice Guideline Update","volume":"38","author":"Key","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/rth2.12102","article-title":"Managing Thrombosis in Cancer Patients","volume":"2","author":"Wang","year":"2018","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12959-025-00719-7","article-title":"Cancer-Associated Venous Thromboembolism: A Comprehensive Review","volume":"23","author":"Wan","year":"2025","journal-title":"Thromb. J."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Mauriello, A., Correra, A., Quagliariello, V., Iovine, M., Di Micco, P., Imbalzano, E., Giallauria, F., Giordano, A., Russo, V., and D\u2019Andrea, A. (2025). Atrial Fibrillation and Cancer: Pathophysiological Mechanism and Clinical Implications. J. Clin. Med., 14.","DOI":"10.3390\/jcm14155600"},{"key":"ref_9","first-page":"56","article-title":"Long-Term Use of Tinzaparin for the Treatment of Cancer-Associated Thrombosis in Clinical Practice: Insights from the Prospective TROPIQUE Study","volume":"47","author":"Frere","year":"2022","journal-title":"JMV-J. De M\u00e9d. Vasc."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2582923","DOI":"10.1155\/2022\/2582923","article-title":"Cancer-Associated Thrombosis: Not All Low-Molecular-Weight Heparins Are the Same, Focus on Tinzaparin, A Narrative Review","volume":"2022","author":"Fioretti","year":"2022","journal-title":"Int. J. Clin. Pract."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/00001573-199409000-00017","article-title":"Low Molecular Weight Heparins","volume":"9","author":"Cosmi","year":"1994","journal-title":"Curr. Opin. Cardiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.2165\/11203710-000000000-00000","article-title":"Tinzaparin Sodium","volume":"70","author":"Hoy","year":"2010","journal-title":"Drugs"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1177\/1076029617729215","article-title":"The Role of Tinzaparin in Oncology","volume":"24","author":"Dimakakos","year":"2018","journal-title":"Clin. Appl. Thromb.\/Hemost."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/1158581-S0-000000000-00000","article-title":"Bemiparin","volume":"70","year":"2010","journal-title":"Drugs"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus Warfarin in Patients with Atrial Fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus Warfarin in Patients with Atrial Fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus Warfarin in Patients with Atrial Fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.2015.9243","article-title":"Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer","volume":"314","author":"Lee","year":"2015","journal-title":"JAMA"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.amjmed.2006.02.022","article-title":"Long-Term Low-Molecular-Weight Heparin versus Usual Care in Proximal-Vein Thrombosis Patients with Cancer","volume":"119","author":"Hull","year":"2006","journal-title":"Am. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.amjmed.2008.12.023","article-title":"Home Therapy of Venous Thrombosis with Long-Term LMWH versus Usual Care: Patient Satisfaction and Post-Thrombotic Syndrome","volume":"122","author":"Hull","year":"2009","journal-title":"Am. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Lee, A.Y., Bauersachs, R., Janas, M.S., Jarner, M.F., Kamphuisen, P.W., Meyer, G., and Khorana, A.A. (2013). CATCH: A Randomised Clinical Trial Comparing Long-Term Tinzaparin versus Warfarin for Treatment of Acute Venous Thromboembolism in Cancer Patients. BMC Cancer, 13.","DOI":"10.1186\/1471-2407-13-284"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.thromres.2016.06.005","article-title":"Low-Molecular-Weight Heparins for Cancer-Associated Thrombosis: Adherence to Clinical Practice Guidelines and Patient Perception in TROPIQUE, a 409-Patient Prospective Observational Study","volume":"144","author":"Cajfinger","year":"2016","journal-title":"Thromb. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.thromres.2017.07.004","article-title":"Tinzaparin in Cancer Associated Thrombosis beyond 6 Months: TiCAT Study","volume":"157","year":"2017","journal-title":"Thromb. Res."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Mah\u00e9, I., Plaisance, L., Chapelle, C., Laporte, S., Planquette, B., Bertoletti, L., Couturaud, F., Falvo, N., Falchero, L., and Mah\u00e9, I. (2020). Long-Term Treatment of Cancer-Associated Thrombosis (CAT) Beyond 6 Months in the Medical Practice: USCAT, a 432-Patient Retrospective Non-Interventional Study. Cancers, 12.","DOI":"10.3390\/cancers12082256"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Cotter, J., Dineen, A., and Marchocki, Z. (2024, January 6\u20139). EV420\/#706 To Evaluate Clinical Effectiveness, Safety and Patients Experience with Apixaban, for Extended VTE Prophylaxis, after Major Surgeries for Gynaecologic Malignancies. Proceedings of the E-Poster Viewing Abstracts, Florence, Italy.","DOI":"10.1136\/ijgc-2024-IGCS.541"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ejvs.2004.02.029","article-title":"Long-Term Treatment of Deep Venous Thrombosis with a Low Molecular Weight Heparin (Tinzaparin): A Prospective Randomized Trial","volume":"29","author":"Daskalopoulos","year":"2005","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s11606-016-3603-8","article-title":"Effects of Long-Term Low-Molecular-Weight Heparin on Fractures and Bone Density in Non-Pregnant Adults: A Systematic Review with Meta-Analysis","volume":"31","author":"Phua","year":"2016","journal-title":"J. Gen. Intern. Med."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Liu, L., Zheng, H., Chen, S., Wang, S., and Yang, M. (2023). Heparin-Induced Thrombocytopenia Associated with Low-Molecular-Weight Heparin: Clinical Feature Analysis of Cases and Pharmacovigilance Assessment of the FAERS Database. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1247253"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1177\/1076029617696581","article-title":"Tinzaparin for Long-Term Treatment of Venous Thromboembolism in Patients with Cancer: A Systematic Review and Meta-Analysis","volume":"24","author":"Mathioudakis","year":"2018","journal-title":"Clin. Appl. Thromb. \/Hemost."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1538-7836.2011.04182.x","article-title":"Individual Patient Data Meta-analysis of Enoxaparin vs. Unfractionated Heparin for Venous Thromboembolism Prevention in Medical Patients","volume":"9","author":"Laporte","year":"2011","journal-title":"J. Thromb. Haemost."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e12736","DOI":"10.1002\/rth2.12736","article-title":"Enoxaparin versus Dalteparin or Tinzaparin in Patients with Cancer and Venous Thromboembolism: The RIETECAT Study","volume":"6","author":"Pedrajas","year":"2022","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.thromres.2011.03.002","article-title":"Safety Profile of Tinzaparin versus Subcutaneous Unfractionated Heparin in Elderly Patients with Impaired Renal Function Treated for Acute Deep Vein Thrombosis: The Innohep\u00ae in Renal Insufficiency Study (IRIS)","volume":"128","author":"Leizorovicz","year":"2011","journal-title":"Thromb. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s11060-009-9911-7","article-title":"Tinzaparin Prophylaxis against Venous Thromboembolic Complications in Brain Tumor Patients","volume":"95","author":"Perry","year":"2009","journal-title":"J. Neurooncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1182\/bloodadvances.2022008644","article-title":"The Prevalence of Thrombocytopenia in Patients with Acute Cancer-Associated Thrombosis","volume":"7","author":"Hsu","year":"2023","journal-title":"Blood Adv."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1182\/bloodadvances.2019001373","article-title":"Comparing Low-Molecular-Weight Heparin Dosing for Treatment of Venous Thromboembolism in Patients with Obesity (RIETE Registry)","volume":"4","author":"Mirza","year":"2020","journal-title":"Blood Adv."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","article-title":"Venous Thromboembolism in Cancer Patients: ESMO Clinical Practice Guideline","volume":"34","author":"Falanga","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.23.00294","article-title":"Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer: ASCO Guideline Update","volume":"41","author":"Key","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_40","first-page":"1181","article-title":"Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Streiff","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"277","DOI":"10.5152\/tud.2020.20030","article-title":"Comparison of Venous Thromboembolic Complications Following Urological Surgery between Patients with or without Cancer","volume":"46","author":"Thomsen","year":"2020","journal-title":"T\u00fcrk Urol. Derg. \/ Turk. J. Urol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Quintana, J.M., Ant\u00f3n-Ladislao, A., Gonz\u00e1lez, N., L\u00e1zaro, S., Bar\u00e9, M., Fern\u00e1ndez-de-Larrea, N., Redondo, M., Briones, E., Escobar, A., and Sarasqueta, C. (2018). Predictors of One and Two Years\u2019 Mortality in Patients with Colon Cancer: A Prospective Cohort Study. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0199894"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e070022","DOI":"10.1136\/bmj-2022-070022","article-title":"Anticoagulants for Thrombosis Prophylaxis in Acutely Ill Patients Admitted to Hospital: Systematic Review and Network Meta-Analysis","volume":"378","author":"Eck","year":"2022","journal-title":"BMJ"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.amjmed.2021.06.003","article-title":"The Impact of Strong Inducers on Direct Oral Anticoagulant Levels","volume":"134","author":"Sennesael","year":"2021","journal-title":"Am. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to Prevent Venous Thromboembolism in Patients with Cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","article-title":"Antithrombotic Therapy for VTE Disease","volume":"160","author":"Stevens","year":"2021","journal-title":"Chest"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1182\/bloodadvances.2024015328","article-title":"American Society of Hematology\/International Society on Thrombosis and Haemostasis 2024 Updated Guidelines for Treatment of Venous Thromboembolism in Pediatric Patients","volume":"9","author":"Monagle","year":"2025","journal-title":"Blood Adv."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/19\/6695\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:47:34Z","timestamp":1760035654000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/19\/6695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,23]]},"references-count":47,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["jcm14196695"],"URL":"https:\/\/doi.org\/10.3390\/jcm14196695","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,23]]}}}